|
1
|
Wolfgang CL, Herman JM, Laheru DA, et al:
Recent progress in pancreatic cancer. CA Cancer J Clin. 63:318–348.
2013. View Article : Google Scholar
|
|
2
|
Maeda S, Shinchi H, Kurahara H, et al:
Clinical significance of midkine expression in pancreatic head
carcinoma. Br J Cancer. 97:405–411. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maeda S, Shinchi H, Kurahara H, et al:
CD133 expression is correlated with lymph node metastasis and
vascular endothelial growth factor-C expression in pancreatic
cancer. Br J Cancer. 98:1389–1397. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hong SP, Wen J, Bang S, Park S and Song
SY: CD44-positive cells are responsible for gemcitabine resistance
in pancreatic cancer cells. Int J Cancer. 125:2323–2331. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Khorana AA, Ahrendt SA, Ryan CK, et al:
Tissue factor expression, angiogenesis, and thrombosis in
pancreatic cancer. Clin Cancer Res. 13:2870–2875. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Collins AT, Berry PA, Hyde C, Stower MJ
and Maitland NJ: Prospective identification of tumorigenic prostate
cancer stem cells. Cancer Res. 65:10946–10951. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ferrandina G, Bonanno G, Pierelli L, et
al: Expression of CD133-1 and CD133-2 in ovarian cancer. Int J
Gynecol Cancer. 18:506–514. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Florek M, Haase M, Marzesco AM, et al:
Prominin-1/CD133, a neural and hematopoietic stem cell marker, is
expressed in adult human differentiated cells and certain types of
kidney cancer. Cell Tissue Res. 319:15–26. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ieta K, Tanaka F, Haraguchi N, et al:
Biological and genetic characteristics of tumor-initiating cells in
colon cancer. Ann Surg Oncol. 15:638–648. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma S, Chan KW, Hu L, et al: Identification
and characterization of tumorigenic liver cancer stem/progenitor
cells. Gastroenterology. 132:2542–2556. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Singh SK, Clarke ID, Terasaki M, et al:
Identification of a cancer stem cell in human brain tumors. Cancer
Res. 63:5821–5828. 2003.PubMed/NCBI
|
|
12
|
Singh SK, Hawkins C, Clarke ID, et al:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Haraguchi N, Ohkuma M, Sakashita H, et al:
CD133+CD44+ population efficiently enriches
colon cancer initiating cells. Ann Surg Oncol. 15:2927–2933.
2008.
|
|
14
|
Pilati P, Mocellin S, Bertazza L, et al:
Prognostic value of putative circulating cancer stem cells in
patients undergoing hepatic resection for colorectal liver
metastasis. Ann Surg Oncol. 19:402–408. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Screaton GR, Bell MV, Jackson DG, Cornelis
FB, Gerth U and Bell JI: Genomic structure of DNA encoding the
lymphocyte homing receptor CD44 reveals at least 12 alternatively
spliced exons. Proc Natl Acad Sci USA. 89:12160–12164. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Screaton GR, Bell MV, Bell JI and Jackson
DG: The identification of a new alternative exon with highly
restricted tissue expression in transcripts encoding the mouse
Pgp-1 (CD44) homing receptor. Comparison of all 10 variable exons
between mouse, human, and rat. J Biol Chem. 268:12235–12238.
1993.
|
|
17
|
Rall CJ and Rustgi AK: CD44 isoform
expression in primary and metastatic pancreatic adenocarcinoma.
Cancer Res. 55:1831–1835. 1995.PubMed/NCBI
|
|
18
|
Bhatavdekar JM, Patel DD, Chikhlikar PR,
et al: Overexpression of CD44: a useful independent predictor of
prognosis in patients with colorectal carcinomas. Ann Surg Oncol.
5:495–501. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Seiter S, Arch R, Reber S, et al:
Prevention of tumor metastasis formation by anti-variant CD44. J
Exp Med. 177:443–455. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gunthert U, Hofmann M, Rudy W, et al: A
new variant of glycoprotein CD44 confers metastatic potential to
rat carcinoma cells. Cell. 65:13–24. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tremmel M, Matzke A, Albrecht I, et al: A
CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and
angiogenesis. Blood. 114:5236–5244. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Alves CS, Yakovlev S, Medved L and
Konstantopoulos K: Biomolecular characterization of
CD44-fibrin(ogen) binding: distinct molecular requirements mediate
binding of standard and variant isoforms of CD44 to immobilized
fibrin(ogen). J Biol Chem. 284:1177–1189. 2009. View Article : Google Scholar
|
|
23
|
Alves CS, Burdick MM, Thomas SN, Pawar P
and Konstantopoulos K: The dual role of CD44 as a functional
P-selectin ligand and fibrin receptor in colon carcinoma cell
adhesion. Am J Physiol Cell Physiol. 294:C907–C916. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hanley WD, Napier SL, Burdick MM, Schnaar
RL, Sackstein R and Konstantopoulos K: Variant isoforms of CD44 are
P- and L-selectin ligands on colon carcinoma cells. FASEB J.
20:337–339. 2006.PubMed/NCBI
|
|
25
|
Nemerson Y: Tissue factor and hemostasis.
Blood. 71:1–8. 1988.PubMed/NCBI
|
|
26
|
Carson SD and Brozna JP: The role of
tissue factor in the production of thrombin. Blood Coagul
Fibrinolysis. 4:281–292. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Milsom CC, Yu JL, Mackman N, et al: Tissue
factor regulation by epidermal growth factor receptor and
epithelial-to-mesenchymal transitions: effect on tumor initiation
and angiogenesis. Cancer Res. 68:10068–10076. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Milsom C, Magnus N, Meehan B, Al-Nedawi K,
Garnier D and Rak J: Tissue factor and cancer stem cells: is there
a linkage? Arterioscler Thromb Vasc Biol. 29:2005–2014. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Milsom C, Yu J, May L, et al: The role of
tumor-and host-related tissue factor pools in oncogene-driven tumor
progression. Thromb Res. 120(Suppl 2): S82–S91. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Milsom C, Anderson GM, Weitz JI and Rak J:
Elevated tissue factor procoagulant activity in CD133-positive
cancer cells. J Thromb Haemost. 5:2550–2552. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Seto S, Onodera H, Kaido T, et al: Tissue
factor expression in human colorectal carcinoma: correlation with
hepatic metastasis and impact on prognosis. Cancer. 88:295–301.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nitori N, Ino Y, Nakanishi Y, et al:
Prognostic significance of tissue factor in pancreatic ductal
adenocarcinoma. Clin Cancer Res. 11:2531–2539. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Oliveira LR, Castilho-Fernandes A,
Oliveira-Costa JP, Soares FA, Zucoloto S and Ribeiro-Silva A:
CD44+/CD133+immunophenotype and matrix
metalloproteinase-9 influences on prognosis of early stage oral
squamous cell carcinoma patients. Head Neck. Nov 1–2013.(Epub ahead
of print).
|
|
34
|
Rentala S, Chintala R, Guda M, Chintala M,
Komarraju AL and Mangamoori LN: Atorvastatin inhibited
Rho-associated kinase 1 (ROCK1) and focal adhesion kinase (FAK)
mediated adhesion and differentiation of CD133CD44 prostate cancer
stem cells. Biochem Biophys Res Commun. 441:586–592. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu Q, Li JG, Zheng XY, Jin F and Dong HT:
Expression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast
carcinomas. Chin Med J. 122:2763–2769. 2009.PubMed/NCBI
|
|
36
|
Lee SM, Lee KE, Chang HJ, et al:
Prognostic significance of CD44s expression in biliary tract
cancers. Ann Surg Oncol. 15:1155–1160. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gansauge F, Gansauge S, Zobywalski A, et
al: Differential expression of CD44 splice variants in human
pancreatic adenocarcinoma and in normal pancreas. Cancer Res.
55:5499–5503. 1995.PubMed/NCBI
|
|
38
|
Saigusa S, Tanaka K, Toiyama Y, et al:
Correlation of CD133, OCT4, and SOX2 in rectal cancer and their
association with distant recurrence after chemoradiotherapy. Ann
Surg Oncol. 16:3488–3498. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Miki J, Furusato B, Li H, et al:
Identification of putative stem cell markers, CD133 and CXCR4, in
hTERT-immortalized primary nonmalignant and malignant tumor-derived
human prostate epithelial cell lines and in prostate cancer
specimens. Cancer Res. 67:3153–3161. 2007. View Article : Google Scholar
|
|
40
|
Hermann PC, Huber SL, Herrler T, et al:
Distinct populations of cancer stem cells determine tumor growth
and metastatic activity in human pancreatic cancer. Cell Stem Cell.
1:313–323. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sun Y, Han J, Lu Y, Yang X and Fan M:
Biological characteristics of a cell subpopulation in tongue
squamous cell carcinoma. Oral Dis. 18:169–177. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu Y, Jiang P, Capkova K, et al: Tissue
factor-activated coagulation cascade in the tumor microenvironment
is critical for tumor progression and an effective target for
therapy. Cancer Res. 71:6492–6502. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rong Y, Post DE, Pieper RO, Durden DL, Van
Meir EG and Brat DJ: PTEN and hypoxia regulate tissue factor
expression and plasma coagulation by glioblastoma. Cancer Res.
65:1406–1413. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fernandez PM and Rickles FR: Tissue factor
and angiogenesis in cancer. Curr Opin Hematol. 9:401–406. 2002.
View Article : Google Scholar : PubMed/NCBI
|
